NCT00083941 2020-10-19
A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer
Oxford BioMedica
Phase 2 Completed
Clinical Trials
8 trialsNCT00325507 2020-10-19
Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma
Oxford BioMedica
Phase 2 Completed
NCT00397345 2020-10-19
TroVax Renal Immunotherapy Survival Trial
Oxford BioMedica
Phase 3 Completed
NCT01194960 2020-10-19
TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)
Oxford BioMedica
Phase 2 Terminated
NCT02390063 2020-02-10
Vaccination in Prostate Cancer (VANCE)
University of Oxford
Phase 1 Completed
NCT00445523 2016-03-17
Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer
The Methodist Hospital Research Institute
Phase 2 Completed
NCT00448409 2016-03-17
Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer
The Methodist Hospital Research Institute
Phase 2 Completed
NCT00521274 2016-03-17
Study of Trovax® Plus Docetaxel Versus Docetaxel Alone in Patients With Progressive Hormone Refractory Prostate Cancer
The Methodist Hospital Research Institute
Phase 2 Terminated